Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
25+ transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Young Jonathan | Chief Operating Officer | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 47,573 | Not reported | No price reported | 0Direct | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Young Jonathan | Chief Operating Officer | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 20,000 | Not reported | No price reported | 0Indirect | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Young Jonathan | Chief Operating Officer | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 20,000 | Not reported | No price reported | 0Indirect, By JL Irrevocable Trust | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Young Jonathan | Chief Operating Officer | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 20,000 | Not reported | No price reported | 0Indirect, By CM Irrevocable Trust | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Young Jonathan | Chief Operating Officer | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 152,616 | Not reported | No price reported | 0Direct, By EA Irrevocable Trust | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Gangloff Scott A. | Chief Technology Officer | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 21,263 | Not reported | No price reported | 0Direct | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Gangloff Scott A. | Chief Technology Officer | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 5,088 | Not reported | No price reported | 0Direct | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Henderson Jane | Director | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 9,398 | Not reported | No price reported | 0Direct | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Cheng Andrew | Director, President and CEO | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 159,762 | Not reported | No price reported | 0Direct | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Cheng Andrew | Director, President and CEO | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 277,075 | Not reported | No price reported | 0Direct | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Lamy Patrick | See Remarks | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 26,832 | Not reported | No price reported | 0Direct | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Lamy Patrick | See Remarks | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 3,059 | Not reported | No price reported | 0Direct | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Graham G. Walmsley | Director | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 9,398 | Not reported | No price reported | 0Direct | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Graham G. Walmsley | Director | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 1,200,000 | Not reported | No price reported | 0Indirect | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Graham G. Walmsley | Director | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 93,000 | Not reported | No price reported | 0Direct, See Footnote | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Harrison Seth Loring | Director | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 9,398 | Not reported | No price reported | 0Direct | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Harrison Seth Loring | Director | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 148,063 | Not reported | No price reported | 0Indirect | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Harrison Seth Loring | Director | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 136,301 | Not reported | No price reported | 0Direct, See Footnote | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Heyman Tomas J. | Director | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 9,398 | Not reported | No price reported | 0Direct | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Yale Catriona | Chief Development Officer | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 47,573 | Not reported | No price reported | 0Direct | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Yale Catriona | Chief Development Officer | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 27,227 | Not reported | No price reported | 0Direct | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Iwicki Mark T | Director | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 9,398 | Not reported | No price reported | 0Direct | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| White William Richard | Chief Financial Officer | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 47,573 | Not reported | No price reported | 0Direct | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| White William Richard | Chief Financial Officer | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 10,179 | Not reported | No price reported | 0Direct | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 | |
| Judy Chou | Director | Akero Therapeutics, Inc. | OtherD · Sale or transfer back to the company | 9,398 | Not reported | No price reported | 0Direct | Form 4 filed 9 Dec 2025, on sec.gov (opens in a new tab)Filed 9 Dec 2025 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.